[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354303-105":59,"doc-detail-354303-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","molecular-insights-and-novel-therapies-for-lymphoproliferative-disorders","Molecular Insights and Novel Therapies for Lymphoproliferative Disorders","","Hematological malignancies cover rare cancers across ages, with subtypes showing age predilections. Next-generation sequencing has revealed molecular and genetic drivers, while epigenetic, transcriptional, and proteomic analyses refine disease mechanisms and pathogenesis. These insights have reshaped lymphoma classification and treatment, enabling targeted agents against clinically relevant molecular vulnerabilities. For eligible patients, stem cell transplantation remains curative potential, with improving safety over time. CAR-T-cell therapy and bispecific antibodies expand immunotherapy, including chemotherapy-free prospects for selected groups.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/molecular-insights-and-novel-therapies-for-lymphoproliferative-disorders/354303/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/molecular-insights-and-novel-therapies-for-lymphoproliferative-disorders/354303.png","ImageObject",300,407,{"name":92,"@type":93},"Mimi","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What molecular tools improved understanding of lymphoma and leukemia in this review?","Question",{"text":112,"@type":113},"Advances in next-generation sequencing, together with epigenetic, transcriptional, and proteomic analyses, and newer single-cell and multiomics approaches improved understanding of disease biology and resistance mechanisms.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which classification systems are highlighted for hematological neoplasms?",{"text":117,"@type":113},"The review discusses the 5th edition WHO Classification (WHO-HAEM5) and the International Consensus Classification (ICC), noting their genetic emphasis and different nomenclature despite broad concordance.",{"name":119,"@type":110,"acceptedAnswer":120},"What treatment advances broadened options beyond chemotherapy in this review?",{"text":121,"@type":113},"The review highlights targeted agents, stem cell transplantation for eligible patients, CAR-T-cell therapy, and bispecific antibodies, and it explores chemotherapy-free approaches in carefully selected groups.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},354303,1790195550,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},2336477974920,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Review  \nMolecular Insights and Novel Therapies for Lymphoproliferative Disorders  \nShucen Wan  and Seema Naik *  \nAcademic Editor: Valentina Giudice  \nReceived: 13 April 2026  \nRevised: 21 May 2026  \nAccepted: 24 May 2026  \nPublished: 2 June 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \nPenn State Milton S. Hershey Medical Center, 500 University Dr, Hershey, PA 17033, USA  \n* Correspondence: [snaik@pennstatehealth.psu.edu](snaik@pennstatehealth.psu.edu)  \nAbstract  \nHematological malignancies encompass a broad spectrum of relatively rare cancers with diverse biological and clinical characteristics that are capable of affecting individuals across all age groups, though certain subtypes show a predilection for specific age ranges. Advances in next-generation sequencing have greatly enhanced our understanding of the molecular and genetic basis of these diseases, while epigenetic, transcriptional, and proteomic analyses have further clarified their pathogenesis. These developments have shaped the classification and treatment of lymphoma. Updated classification frameworks which include the identification of clinically relevant molecular targets have opened the door to a number of targeted agents, each designed to exploit specific vulnerabilities within malignant cells, while stem cell transplantation continues to offer curative potential for eligible patients, with improving safety profiles over time. CAR-T-cell therapy has been extended to multiple blood cancer indications, achieving lasting remissions in patients with previously exhausted treatment options. Bispecific antibodies have further broadened the immunotherapy landscape by redirecting the body’s own T cells against tumor cells, offering a readily available alternative that overcomes many of the practical limitations associated with CAR-T-cell production. The ability to combine these strategies has fundamentally changed what is achievable in blood cancer treatment, with long-term remission now a realistic goal for many patients. This review seeks to outline the core molecular mechanisms underlying lymphoma and leukemia, evaluate currently approved treatment options, discuss significant ongoing clinical trials with practice-changing potential, and explore the prospect of chemotherapy-free approaches in carefully selected patient groups.  \nKeywords: diffuse large B-cell lymphoma (DLBCL); follicular lymphoma (FL); mantle cell lymphoma (MCL); chimeric antigen receptor T cell therapy (CART); molecular mechanisms; hematological malignancies; targeted therapies  \n1. Introduction  \nHematological malignancies encompass a broad spectrum of relatively rare cancers with diverse biological and clinical characteristics that are capable of affecting individuals across all age groups, though certain subtypes show a predilection for specific age ranges. Advances in next-generation sequencing have greatly enhanced our understanding of the molecular and genetic basis of these diseases, while epigenetic, transcriptional, and proteomic analyses have further clarified their pathogenesis [1,2] . The emergence of single-cell technologies and multiomics approaches [3,4], supported by robust bioinformatic tools, has provided deeper insight into disease initiation, progression, and treatment resistance.  \nCollectively, these developments have not only improved diagnostic accuracy and enabled earlier disease detection, but have also transformed disease monitoring through liquid biopsy and circulating tumor DNA analysis, offering valuable prognostic and predictive information throughout the disease course [5,6] . These developments have shaped both how hematological malignancies are classified and how they are treated. The classification of hematological neoplasms has undergone significant transformation, driven by advancesin molecular","cbCaijqbT4E3JgzR","https://ap.wps.com/l/cbCaijqbT4E3JgzR","pdf",433006,22,"English","# Introduction\n## Molecular diagnostics and next-generation sequencing\n## Classification frameworks (WHO-HAEM5 and ICC)\n## Targeted agents and immunotherapies","[{\"question\":\"What molecular tools improved understanding of lymphoma and leukemia in this review?\",\"answer\":\"Advances in next-generation sequencing, together with epigenetic, transcriptional, and proteomic analyses, and newer single-cell and multiomics approaches improved understanding of disease biology and resistance mechanisms.\"},{\"question\":\"Which classification systems are highlighted for hematological neoplasms?\",\"answer\":\"The review discusses the 5th edition WHO Classification (WHO-HAEM5) and the International Consensus Classification (ICC), noting their genetic emphasis and different nomenclature despite broad concordance.\"},{\"question\":\"What treatment advances broadened options beyond chemotherapy in this review?\",\"answer\":\"The review highlights targeted agents, stem cell transplantation for eligible patients, CAR-T-cell therapy, and bispecific antibodies, and it explores chemotherapy-free approaches in carefully selected groups.\"}]","Molecular Insights and Novel Therapies for Lymphoproliferative Disorders | PDF",1790109965,55,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a12aa142bd8f3d02ec88b96c426298eb.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e0e34c3196a281f742ee328cd609abcd.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e5c661e8e0fa755b92d65059885687d3.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5a878638c19f67ed956aeca6201ea85f.webp",980,1385]